Cordis buys new blood clot capture technology:
This article was originally published in Clinica
Executive Summary
Cordis has acquired AngioGuard, a Minneapolis, Minnesota-based developer of embolic containment systems, for an undisclosed amount. The system is designed to prevent a possible stroke by capturing blood clots which become dislodged during interventional procedures such as carotid stenting and saphenous vein graft stenting. It is approved for coronary applications in Europe and Cordis expects to receive approval later this year for carotid applications. The Warren, New Jersey-based company hopes to combine its carotid stents, which are currently undergoing US clinical trials, with the newly-acquired technology.